The Latest Breaking News from NVO

Novo Nordisk (NYSE:NVO) has outperformed the market over the past 10 years by 3.35% on an annualized basis producing an average annual return of 14.11%. Currently, Novo Nordisk has a market capitalization of $238.19 billion.

The better-than-expected May employment report indicates that the Federal Reserve will continue to raise interest rates aggressively this year. Since the fears of an economic slowdown are expected to keep the stock market extremely volatile, it could be wise to bet on high-quality large-cap stocks McKesson (MCK), Novo Nordisk (NVO),…

This is the moment Russian troops fire mortar rounds at Ukrainian targets.

Novo Nordisk (NYSE:NVO) has outperformed the market over the past 10 years by 2.43% on an annualized basis producing an average annual return of 14.2%. Currently, Novo Nordisk has a market capitalization of $253.71 billion.

The Fed’s aggressive interest rate hikes and high energy prices will likely fuel recessionary conditions. Moreover, the unexpected decline in GDP in the first quarter indicates a possible economic contraction. Amid such possibilities, the pharmaceutical industry could attract investors’ attention because of the inelastic demand for its products. Today, I…

Novo Nordisk A/S (NYSE:NVO) has announced topline results from Phase 3a ONWARDS 2 trial, 26-week efficacy and safety treat-to-target trial investigating once-weekly insulin icodec vs. insulin degludec. The study included 526 people with type 2 diabetes switching from daily insulin. The trial achieved its primary endpoint of demonstrating non-inferiority in reducing HbA1c at…

The stock market has been experiencing high volatility due to various economic and geopolitical factors. But under these uncertain market conditions investors could add quality mega-cap stocks Novo Nordisk (NVO), Shell (SHEL), Eli Lilly (LLY), Novartis (NVS), and Costco (COST) to their watchlists. Mega-cap stocks are known to endure harsh…

Novo Nordisk (NYSE:NVO) has outperformed the market over the past 10 years by 2.28% on an annualized basis producing an average annual return of 14.59%. Currently, Novo Nordisk has a market capitalization of $268.66 billion.

The healthcare industry has attracted massive investor interest since the onset of the COVID-19 pandemic and could remain in the limelight as COVID cases surge again and necessitate the need for more COVID shots. In addition, the healthcare sector is known to withstand recessions relatively well. So, with several analysts…

The FDA has approved Novo Nordisk A/S's (NYSE:NVO) 2.0 mg dose of Ozempic (once-weekly semaglutide subcutaneous injection), a glucagon-like peptide-1 (GLP-1) analog for type 2 diabetes.  Ozempic is now approved in the US at 0.5 mg,1.0 mg, and 2.0 mg doses to treat type 2 diabetes in adults. Further, Ozempic is indicated to…

Novo Nordisk (NYSE:NVO) has outperformed the market over the past 10 years by 2.52% on an annualized basis producing an average annual return of 14.65%. Currently, Novo Nordisk has a market capitalization of $250.29 billion.